Key result
IV methylprednisolone pulsetherapy for severe rheumatic carditis shows a higher recent need for repeated treatment series.
Why the study?
Does IV methylprednisolone pulsetherapy improve outcomes in children with severe active rheumatic carditis?
Cohort (n=70)
Does IV methylprednisolone pulsetherapy improve outcomes in children with severe active rheumatic carditis?
High-dose IV methylprednisolone pulsetherapy remains a useful treatment protocol for severe active rheumatic carditis in children, despite variations in disease presentation over time.
Answers are grounded in this paper and cite their sources.
Caution with rising recent treatment needs; leaves open evolving disease severity or resistance in rheumatic carditis.
PURPOSE: To report the result of patients treated with IV methylprednisolone divided into three groups and compare their follow-up during the last 12 years. METHODS: Seventy children with active rheumatic carditis (76 episodes) in heart failure Class III and IV (NYHA) were studied. The diagnosis was based on modified Jones' criteria. After ruling out infections and strongyloidiasis, treatment with IV methylprednisolone bolus was started three times a week until the laboratory tests became negative. Patients were divided into 3 groups, according to the time of hospital admittance: Groups 1, 2 and 3, comprising of 40, 18 and 12 children, respectively. RESULTS: Eighteen children in Group 1 (45%) were in their 1st attack: 2 series of pulsetherapy were used in 10 (25%), 3 in 9 (23%) and 4 in 21 (52%). In Group 2, 14 cases (77%) were in their 1st attack: 2 series were used in 7 (39%), 4 in 9 (50%) and 5 in 2 (11%). The echocardiogram showed a flail mitral valve in 12 (66%) of these patients (1 death occurred after mitral valvoplasty). In Group 3, 6 patients needed 5 or more series of pulsetherapy and a flail mitral valve was present in 5 (41%). One child underwent mitral valve replacement while still in the active phase, after 8 series of pulsetherapy, and another died. The number of patients who needed 5 or more series was significantly higher in Group 3. CONCLUSION: There were variations in the presentation and evolution of the cases during these 12 year. The established pulsetherapy protocol continues to be useful to treat severe cases.
No takes yet. Share an insight, caveat, or question.
Herdy et al. (1999) conducted a cohort in active rheumatic carditis (n=70). IV methylprednisolone pulsetherapy was evaluated on Need for 5 or more series of pulsetherapy. IV methylprednisolone pulsetherapy for severe rheumatic carditis showed variations in disease evolution over 12 years, with a significantly higher need for ≥5 treatment series in the recent group.
Synapse has enriched 10 related papers. Consider them for comparative context: